HomeCompareORXOY vs GBDC

ORXOY vs GBDC: Dividend Comparison 2026

ORXOY yields 71.43% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $19.65M in total portfolio value· pulled ahead in Year 8
10 years
ORXOY
ORXOY
● Live price
71.43%
Share price
$2.80
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.12M
Annual income
$299,297.66
Full ORXOY calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — ORXOY vs GBDC

📍 GBDC pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORXOYGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORXOY + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORXOY pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORXOY
Annual income on $10K today (after 15% tax)
$6,071.43/yr
After 10yr DRIP, annual income (after tax)
$254,403.01/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,676,470.89/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORXOY + GBDC for your $10,000?

ORXOY: 50%GBDC: 50%
100% GBDC50/50100% ORXOY
Portfolio after 10yr
$10.95M
Annual income
$8,344,280.53/yr
Blended yield
76.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ORXOY
No analyst data
Altman Z
-0.1
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORXOY buys
0
GBDC buys
0
No recent congressional trades found for ORXOY or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORXOYGBDC
Forward yield71.43%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$1.12M$20.78M
Annual income after 10y$299,297.66$16,389,263.41
Total dividends collected$960.2K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ORXOY vs GBDC ($10,000, DRIP)

YearORXOY PortfolioORXOY Income/yrGBDC PortfolioGBDC Income/yrGap
1$17,843$7,142.86$12,490$1,790.28+$5.4KORXOY
2$31,003$11,911.12$16,522$3,157.73+$14.5KORXOY
3$52,515$19,342.29$23,578$5,898.68+$28.9KORXOY
4$86,812$30,620.19$37,115$11,886.75+$49.7KORXOY
5$140,194$47,305.90$66,136$26,423.57+$74.1KORXOY
6$221,406$71,397.66$137,257$66,491.44+$84.1KORXOY
7$342,284$105,380.00$341,734$194,868.54+$550.00ORXOY
8← crossover$518,499$152,255.26$1,050,788$685,133.02$532.3KGBDC
9$770,345$215,550.93$4,099,314$2,974,971.01$3.33MGBDC
10$1,123,567$299,297.66$20,775,530$16,389,263.41$19.65MGBDC

ORXOY vs GBDC: Complete Analysis 2026

ORXOYStock

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Full ORXOY Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ORXOY vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORXOY vs SCHDORXOY vs JEPIORXOY vs OORXOY vs KOORXOY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.